Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Human Genome Sciences Inc., a GSK Company
With
GlaxoSmithKline
This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.
You may not be if
Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.
